Oncotarget

Research Papers:

Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells

Ravyn M. Thompson, Dominik Dytfeld, Leticia Reyes, Reeder M. Robinson, Brittany Smith, Yefim Manevich, Andrzej Jakubowiak, Mieczyslaw Komarnicki, Anna Przybylowicz-Chalecka, Tomasz Szczepaniak, Amit K. Mitra, Brian G. Van Ness, Magdalena Luczak and Nathan G. Dolloff _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:35863-35876. https://doi.org/10.18632/oncotarget.16262

Metrics: PDF 1264 views  |   HTML 1630 views  |   ?  


Abstract

Ravyn M. Thompson1, Dominik Dytfeld2, Leticia Reyes1, Reeder M. Robinson1, Brittany Smith1, Yefim Manevich1, Andrzej Jakubowiak3, Mieczyslaw Komarnicki2, Anna Przybylowicz-Chalecka2, Tomasz Szczepaniak2, Amit K. Mitra5, Brian G. Van Ness5, Magdalena Luczak4, Nathan G. Dolloff1,*

1Department of Cell and Molecular Pharmacology & Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, USA

2Karol Marcinkowski University of Medical Sciences, Poznan, Poland

3University of Chicago, Chicago, IL, USA

4Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland

5University of Minnesota, Minneapolis, MN, USA

*These authors contributed equally to this work

Correspondence to:

Nathan G. Dolloff, email: dolloffn@musc.edu

Keywords: multiple myeloma, proteasome inhibitor, glutaminase, carfilzomib

Received: December 08, 2016     Accepted: March 01, 2017     Published: March 16, 2017

ABSTRACT

Curative responses in the treatment of multiple myeloma (MM) are limited by the emergence of therapeutic resistance. To address this problem, we set out to identify druggable mechanisms that convey resistance to proteasome inhibitors (PIs; e.g., bortezomib), which are cornerstone agents in the treatment of MM. In isogenic pairs of PI sensitive and resistant cells, we observed stark differences in cellular bioenergetics between the divergent phenotypes. PI resistant cells exhibited increased mitochondrial respiration driven by glutamine as the principle fuel source. To target glutamine-induced respiration in PI resistant cells, we utilized the glutaminase-1 inhibitor, CB-839. CB-839 inhibited mitochondrial respiration and was more cytotoxic in PI resistant cells as a single agent. Furthermore, we found that CB-839 synergistically enhanced the activity of multiple PIs with the most dramatic synergy being observed with carfilzomib (Crflz), which was confirmed in a panel of genetically diverse PI sensitive and resistant MM cells. Mechanistically, CB-839 enhanced Crflz-induced ER stress and apoptosis, characterized by a robust induction of ATF4 and CHOP and the activation of caspases. Our findings suggest that the acquisition of PI resistance involves adaptations in cellular bioenergetics, supporting the combination of CB-839 with Crflz for the treatment of refractory MM.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16262